Search Results

current research project I use iPSC-derived cardiac fibroblasts to examine cellular signaling in the fibrotic

Retreat Program < Back to schedule Cannabinoid compounds to augment L-DOPA treatment in Parkinson's Disease

Program < Back to schedule Biased agonism at the GLP-1 receptor: from structure to animal models of disease

Sponsors GPCR Retreat Program < Back to schedule Genetic Deletion of Atypical VGLUT3 Rescues Huntington’s Disease coupled receptors and their role in neurodegenerative disorders, including Alzheimer's and Huntington's diseases

and Genetic Preclinical Models of Ghrelin Receptor Functional Selectivity to Investigate Metabolic Disease GPCR biased signaling to design/develop new pharmacotherapeutics to treat reward- and metabolism-based diseases novel GPCR pharmacotherapies that improve efficacy and minimize side effects for diet-induced metabolic diseases

Indian Institute of Science, Bangalore, India, to investigate the mechanisms behind rare mitochondrial diseases at the Cleveland Clinic in Ohio, USA, studying the gut microbiome and its impact on cardiovascular disease gut microbe-derived metabolite called phenylacetylglutamine (PAG), which is linked to cardiovascular disease as targets for more than one-third of all prescribed drugs currently used in the treatment of human diseases

mechanisms underlying biased agonism at GPCRs and its contribution inflammation and cardiovascular disease His clinical focus is on pulmonary arterial hypertension, a disease of the pulmonary arterioles that causes right heart failure, and he serves as co-director of the Duke Pulmonary Vascular Disease Center

the Receptor Biology Lab, focuses on the development of novel GPCR-based therapeutics that interdict diseases basis of a new technology-based start-up company, HeptOME , to help screen and develop novel longevity/disease-regulating compounds with multidimensional disease efficacy profiles.

the Receptor Biology Lab, focuses on the development of novel GPCR-based therapeutics that interdict diseases basis of a new technology-based start-up company, HeptOME , to help screen and develop novel longevity/disease-regulating compounds with multidimensional disease efficacy profiles.

the Receptor Biology Lab, focuses on the development of novel GPCR-based therapeutics that interdict diseases basis of a new technology-based start-up company, HeptOME , to help screen and develop novel longevity/disease-regulating compounds with multidimensional disease efficacy profiles.

of studying metabolites and their receptors, the relationship between metabolites, gut health, and disease They briefly touched upon the link between GPCRs and diseases, such as diabetes, but did not delve into Metabolites, Gut Health, and Disease Progression Yamina and Claudia had a discussion about the relationship between metabolites, gut health, and disease progression. Both agreed on the complexity of the topic, with Claudia concluding that diseases might first affect

multiplexed platform to map GPCR-RAMP interactions and uncover autoantibody-driven GPCR signaling in disease to academic researchers , with wide applicability beyond just RAMPs — including scaffold proteins, disease A Diagnostic Future “Autoantibodies targeting GPCRs might drive disease.” – Tom Sakmar One especially exciting avenue is autoimmune and infectious diseases . tools to detect GPCR autoantibodies , which are implicated in conditions like long COVID and Graves’ disease

, molecular and cellular pharmacology, medicinal chemistry, and preclinical models of behaviour and disease work has been applied to studies encompassing neurological and psychiatric disorders, cardiovascular disease They highlighted the importance of fine-tuning the approach to suit different diseases and interdisciplinary The discussion also emphasized the need for a disease-specific approach, considering the clinical context Arthur and Yamina discussed the potential of autoantibodies and allosteric modulation in the context of disease

during prolonged cold exposure Anastasia Georgiadi ADGRF5-mediated regulation of cardiac health and disease Netherlands; 2Department of Experimental Immunology, Amsterdam institute for Immunology and Infectious diseases Georgiadi on the web Endocrine Pharmacology Google Scholar ADGRF5-mediated regulation of cardiac health and disease

the co-founder of both Caldan Therapeutics (2015) which discovers novel therapeutics for metabolic diseases Type 2 Diabetes and other indications including non-alcoholic steatohepatitis (NASH) and inflammatory diseases

Why receptor localization and scaffolding dramatically shift functional readouts in disease models. with robust validation under real experimental constraints, Tried to map signaling heterogeneity in disease-relevant investigates how GPCRs orchestrate localized signaling events, how these mechanisms are hijacked in disease

research laboratory of around 15 staff supported by basic research grants investigating aspects of disease biology and the action of drugs in the context of disease.

the investigation of the regulation of G protein-coupled receptors signaling mechanisms in health and disease investigating the role of metabotropic glutamate receptor signaling in Huntington’s and Alzheimer’s disease

and pharmacology aiming to understand the role of WNT/Frizzled signaling in biology, physiology, and disease find, create and optimize Frizzled-targeting small molecule drugs to improve future therapies of human disease

laboratory has gained valuable insights into the genetic basis and pathophysiology of lymphatic vascular disease , preeclampsia and sex-dependent cardiovascular disease.

multidisciplinary teams for screening and innovative therapeutics targeting metabolic and cardiovascular diseases Why persistent scientific questioning and collaborative networks accelerate GPCR innovation across disease contributing to projects across key therapeutic areas—spanning metabolic, cardiovascular, and gastrointestinal diseases

and obtained a PhD in Molecular Medicine and a Clinical Specialisation in Endocrinology and Metabolic Disease protein-coupled receptor (GPCR) signalling and their alterations in endocrine, metabolic and cardiovascular diseases

the investigation of the regulation of G protein-coupled receptors signaling mechanisms in health and disease investigating the role of metabotropic glutamate receptor signaling in Huntington’s and Alzheimer’s disease

His clinical focus is on pulmonary arterial hypertension, a disease of the pulmonary arterioles that causes right heart failure, and he serves as co-director of the Duke Pulmonary Vascular Disease Center

gained experience in the identification and characterization of llama-derived antibodies in inflammatory diseases conformations, while also focusing on their therapeutic potential in oncology and transplant infectious disease

laboratory has gained valuable insights into the genetic basis and pathophysiology of lymphatic vascular disease , preeclampsia and sex-dependent cardiovascular disease.

the identification of drugs targeting the unique aGPCR receptor family and customize the method for disease-relevant recruited by Vertex Pharmaceuticals (Canada) where he worked on biomarker discovery for inflammatory bowel disease and small molecules drug discovery for polycystic kidney disease. novel pharmacological targets and contribute to the development of innovative treatments for a range of diseases

She is currently working to understand the signaling and degradation of GPCRs in disease states to help

microdomains modulate GPCR activity, the translational impact of taste receptors in cancer and metabolic diseases mechanistic role of microdomains If you’re expanding functional assays to capture non-canonical GPCR roles in disease

Much of his work is based on GPCR signaling in the context to cardiovascular diseases.